Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial


      • Advanced age enhances the bleeding risk associated with dual antiplatelet therapy.
      • The optimal duration of dual antiplatelet therapy in elderly patients with acute coronary syndromes (ACS) is debated.
      • The REDUCE trial compared 3 vs 12 months DAPT in ACS patients treated with the COMBO Dual Stent Therapy.
      • We provide a sub-analysis of the REDUCE trial according to age.
      • No age-related difference was observed in the primary composite or individual thrombotic and bleeding endpoints at 12 months.


      Background and aims

      The impact of advanced age on the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary revascularization (PCI) is still greatly debated. Therefore, the aim of the present sub-analysis of the REDUCE trial was to assess the impact of age on the comparison between a short 3 months vs standard 12 months DAPT in ACS patients treated with the COMBO Dual Stent Therapy.


      The REDUCE trial is a prospective, multicenter, investigator-initiated study that randomized ACS patients undergoing PCI with the COMBO drug eluting stent to either 3 or 12 months of DAPT. The study population was divided according to age (<or ≥ 75 years). Primary study endpoint was a composite of all-cause mortality, myocardial infarction, definite/probable stent thrombosis (ST), stroke, target-vessel revascularization (TVR) and bleeding (BARC II, III, V) at 12 months. Secondary endpoints were cardiovascular mortality and the individual components of the primary endpoint within 24 months.


      From June 2014 to May 2016, 1496 patients were included in the study, of whom 205 (13.7%) ≥75 years of age. Among them, 50.7% of the elderly and 50.2% of younger patients were assigned to the 3-month DAPT treatment. Baseline characteristics were well matched between the two arms, except for a higher rate of males (p=0.02) and a reduced number of lesions on the right coronary artery (p=0.02) in elderly patients treated for the short DAPT duration. Median follow-up was 682.5 days [IQR:667-731]. At 12 months, no difference in the primary endpoint was observed according to DAPT duration in both patients aged ≥75 years (22.1% vs 18.8%, HR [95%CI] = 1.6 [0.73–3.5], p=0.24) and younger ones (9.7% vs 10.9%, HR [95%CI] = 0.85 [0.59–1.27], p=0.44; p INT = 0.15). Results were confirmed after correction for baseline differences among the elderly (adjusted HR [95%CI] = 1.7 [0.75–3.9], p=0.21). Comparable rates of survival, thrombotic (MI, stent thrombosis, TVR, stroke) and bleeding events were observed with the two DAPT strategies, with no impact of age.


      The present study shows that among ACS patients randomized in the REDUCE trial, a 3-month DAPT strategy was comparable to a standard 12-month DAPT at a 2-year follow-up for both ischemic and bleeding endpoints, in elderly and younger patients. Thus, despite presenting the limitations of a subgroup analysis, our study strengthens the feasibility of a shorter DAPT duration even among high-risk subsets of ACS patients.

      Graphical abstract


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Postma W.
        • Fabris E.
        • Van derEnt M.
        • Hermanides R.
        • Buszman P.
        • Von Birgelen C.C.
        • Cook S.
        • Wedel H.
        • De Luca G.
        • Delewi R.
        • Zijlstra F.
        • Kedhi E.
        Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): a prespecified prospective register from the DAPT-STEMI trial.
        Cathet. Cardiovasc. Interv. 2020; 95 ([Epub ahead of print]): 706-710
        • Verdoia M.
        • Barbieri L.
        • Kedhi E.
        • Suryapranata H.
        • De Luca G.
        Percutaneous versus surgical revascularization for left main or multivessel coronary artery disease: results from a large-scale meta-analysis in the era of drug-eluting stents.
        Angiology. 2018 Oct; 69: 812-824
        • Verdoia M.
        • Schaffer A.
        • Barbieri L.
        • Suryapranata H.
        • De Luca G.
        Bivalirudin versus unfractionated heparin in acute coronary syndromes: an updated meta-analysis of randomized trials.
        Rev. Esp. Cardiol. 2016; 69: 732-745
        • De Luca G.
        • Suryapranata H.
        Recent advances in optimal adjunctive antithrombotic therapy in STEMI patients undergoing primary angioplasty: an overview.
        Curr. Vasc. Pharmacol. 2015; 13: 594-615
        • Verdoia M.
        • Pergolini P.
        • Barbieri L.
        • Rolla R.
        • Nardin M.
        • Negro F.
        • Suryapranata H.
        • De Luca G.
        • Novara Atherosclerosis Study Group (NAS)
        Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
        Thromb. Res. 2018; 164: 17-23
        • Verdoia M.
        • Schaffer A.
        • Barbieri L.
        • Cassetti E.
        • Piccolo R.
        • Galasso G.
        • Marino P.
        • Sinigaglia F.
        • De Luca G.
        Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
        J. Cardiovasc. Pharmacol. 2014; 63: 339-350
        • Palmerini T.
        • Biondi-Zoccai G.
        • Riva D.D.
        • et al.
        Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
        Lancet. 2012; 379: 1393-1402
        • Kedhi E.
        Six versus Twelve Months Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in ST-Elevation Myocardial Infarction Primary Results from the DAPT-STEMI Trial.
        TCT, 2017
        • Verdoia M.
        • Schaffer A.
        • Barbieri L.
        • Montalescot G.
        • Collet J.P.
        • Colombo A.
        • Suryapranata H.
        • De Luca G.
        Optimal duration of dual antiplatelet therapy after DES implantation: a meta-analysis of 11 randomized trials.
        Angiology. 2016; 67: 224-238
        • Capodanno D.
        • Alfonso F.
        • Levine G.N.
        • Valgimigli M.
        • Angiolillo D.J.
        ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison.
        J. Am. Coll. Cardiol. 2018 Dec 11; 72: 2915-2931
        • Costa F.
        • Van Klaveren D.
        • Feres F.
        • James S.
        • Räber L.
        • Pilgrim T.
        • Hong M.K.
        • KimHS
        • Colombo A.
        • Steg P.G.
        • Bhatt D.L.
        • Stone G.W.
        • Windecker S.
        • Steyerberg E.W.
        • Valgimigli M.
        PRECISE-DAPT study investigators. Dual antiplatelet Therapy Duration based on ischemic and bleeding risks after coronary stenting.
        J. Am. Coll. Cardiol. 2019; 73: 741-754
        • Sibbing D.
        • Aradi D.
        • Alexopoulos D.
        • Ten Berg J.
        • Bhatt D.L.
        • Bonello L.
        • Collet J.P.
        • Cuisset T.
        • Franchi F.
        • Gross L.
        • Gurbel P.
        • Jeong Y.H.
        • Mehran R.
        • Moliterno D.J.
        • Neumann F.J.
        • Pereira N.L.
        • Price M.J.
        • Sabatine M.S.
        • So D.Y.F.
        • Stone G.W.
        • Storey R.F.
        • Tantry U.
        • Trenk D.
        • Valgimigli M.
        • Waksman R.
        • Angiolillo D.J.
        Updated Expert Consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention.
        JACC Cardiovasc. Interv. 2019; 12: 1521-1537
        • Andreotti F.
        • Rocca B.
        • Husted S.
        • et al.
        • ESC Thrombosis Working Group
        Antithrombotic therapy in the elderly: expert position paper of the European society of cardiology working group on thrombosis.
        Eur. Heart J. 2015; 36: 3238-3249
      1. De Luca L, Leonardi S, Smecca IM, et al.; EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. Eur Heart J CardiovascPharmacother2015;1:168-178.

        • Tarantini G.
        • Cirillo P.
        • De Servi S.
        • Parodi G.
        • Capodanno D.
        • D'Amico G.
        • et al.
        Dual antiplatelet therapy in elderly patients with acute coronary syndrome: does age make the difference?.
        Giorn. Ital. Cardiol. 2006; 19: 420-428
        • De Luca G.
        • Damen S.A.
        • Camaro C.
        • Benit E.
        • Verdoia M.
        • Rasoul S.
        • Liew H.B.
        • Polad J.
        • Ahmad W.A.
        • Zambahari R.
        • Postma S.
        • Kedhi E.
        • Suryapranata H.
        • Collaborators
        Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial.
        EuroIntervention. 2019 Aug 20; (pii: EIJ-D-19-00539) ([Epub ahead of print])
        • Camaro C.
        • Damen S.A.
        • Brouwer M.A.
        • et al.
        Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
        Am. Heart J. 2016; 178: 37-44
      2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American college of cardiology/American heart association task force on practice guidelines (committee on the management of patients with unstable Angina). J AmCollCardiol2000;36:970-1062.

        • Thygesen K.
        • Alpert J.S.
        • Jaffe A.S.
        • et al.
        Joint ESC/ACCF/AHA/WHF task force for the universal definition of myocardial infarction. Third universal definition of myocardial infarction.
        Circulation. 2012; 126: 2020-2035
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • et al.
        Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Mehran R.
        • Rao S.V.
        • Bhatt D.L.
        • et al.
        Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
        Circulation. 2011; 123: 2736-2747
        • Di Chiara A.
        • Fresco C.
        • Savonitto S.
        • et al.
        BLITZ-2 Investigators. Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study.
        Eur. Heart J. 2006; 27: 393-405
        • Bortnick A.E.
        • Epps K.C.
        • Selzer F.
        • Anwaruddin S.
        • Marroquin O.C.
        • Srinivas V.
        • Holper E.M.
        • Wilensky R.L.
        Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity.
        Am. J. Cardiol. 2014; 113: 573-579
        • De Luca G.
        • Dirksen M.T.
        • Spaulding C.
        • Kelbæk H.
        • Schalij M.
        • Thuesen L.
        • van der Hoeven B.
        • Vink M.A.
        • Kaiser C.
        • Musto C.
        • Chechi T.
        • Spaziani G.
        • Diaz de la Llera L.S.
        • Pasceri V.
        • Di Lorenzo E.
        • Violini R.
        • Suryapranata H.
        • Stone G.W.
        DESERT cooperation. Impact of age on long-term outcome after primary angioplasty with bare-metal or drug-eluting stent.
        Am. J. Cardiol. 2013; 112: 181-186
        • De Luca G.
        • van'tHof A.W.
        • Huber K.
        • Gibson C.M.
        • Bellandi F.
        • Arntz H.R.
        • Maioli M.
        • Noc M.
        • Zorman S.
        • Secco G.G.
        • Zeymer U.
        • Gabriel H.M.
        • Emre A.
        • Cutlip D.
        • Rakowski T.
        • Gyongyosi M.
        • Dudek D.
        Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.
        Heart Ves. 2014; 29: 15-20
        • Avezum A.
        • Makdisse M.
        • Spencer F.
        • Gore J.M.
        • Fox K.A.
        • Montalescot G.
        • Eagle K.A.
        • White K.
        • Mehta R.H.
        • Knobel E.
        • Collet J.P.
        Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE).
        Am. Heart J. 2005; : 67-73
        • De Luca G.
        • van 't Hof A.W.
        • Ottervanger J.P.
        • Hoorntje J.C.
        • Gosselink A.T.
        • Dambrink J.H.
        • de Boer M.J.
        • Suryapranata H.
        Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty.
        Eur. Heart J. 2005 Apr; 26: 662-666
        • Verdoia M.
        • Pergolini P.
        • Rolla R.
        • Nardin M.
        • Schaffer A.
        • Barbieri L.
        • Marino P.
        • Bellomo G.
        • Suryapranata H.
        • De Luca G.
        Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
        J. Thromb. Haemostasis. 2016 Jan; 14: 57-64
        • De Luca L.
        • Marini M.
        • Gonzini L.
        • et al.
        Contemporary trends and age-specific sex differences in management and outcome for patients with ST-segment elevation myocardial infarction.
        J Am Heart Assoc. 2016; (epub Nov 23)
      3. Savonitto S, Cavallini C, Petronio AS, et al, For the Italian Elderly ACS Trial Investigators. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC CardiovascInterv2012;5:906-916.

        • Tegn N.
        • Abdelnoor M.
        • Aaberge L.
        • et al.
        After Eighty study investigators. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomized controlled trial.
        Lancet. 2016; 387: 1057-1065
        • Moalem K.
        • Baber U.
        • Chandrasekhar J.
        • Claessen B.E.
        • Sartori S.
        • Aquino M.
        • Dangas G.
        • Iakovou I.
        • Colombo A.
        • Kini A.
        • Gibson M.
        • Krucoff M.
        • Chieffo A.
        • Moliterno D.
        • Witzenbichler B.
        • Pocock S.
        • Mehran R.
        Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
        Clin. Res. Cardiol. 2019 Jun; 108: 643-650ù
        • Valgimigli M.
        • Bueno H.
        • Byrne R.A.
        • Collet J.P.
        • Costa F.
        • Jeppsson A.
        • Jüni P.
        • Kastrati A.
        • Kolh P.
        • Mauri L.
        • Montalescot G.
        • Neumann F.J.
        • Petricevic M.
        • Roffi M.
        • Steg P.G.
        • Windecker S.
        • Zamorano J.L.
        • Levine G.N.
        ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).
        Eur. Heart J. 2018; 39: 213-260
        • Urban P.
        • Mehran R.
        • Colleran R.
        • Angiolillo D.J.
        • Byrne R.A.
        • Capodanno D.
        • CuissetT
        • Cutlip D.
        • Eerdmans P.
        • Eikelboom J.
        • Farb A.
        • Gibson C.M.
        • Gregson J.
        • Haude M.
        • James S.K.
        • Kim H.S.
        • Kimura T.
        • Konishi A.
        • Laschinger J.
        • Leon M.B.
        • Magee P.F.A.
        • Mitsutake Y.
        • Mylotte D.
        • Pocock S.
        • Price M.J.
        • Rao S.V.
        • Spitzer E.
        • Stockbridge N.
        • Valgimigli M.
        • Varenne O.
        • Windhoevel U.
        • Yeh R.W.
        • Krucoff M.W.
        • Morice M.C.
        Defining high bleeding risk in patients undergoing percutaneous coronary intervention circulation.
        . 2019 Jul 16; 140: 240-261
        • Dewilde W.J.
        • Oirbans T.
        • Verheugt F.W.
        • Kelder J.C.
        • De Smet B.J.
        • Herrman J.P.
        • Adriaenssens T.
        • Vrolix M.
        • Heestermans A.A.
        • Vis M.M.
        • Tijsen J.G.
        • van 't Hof A.W.
        • ten Berg J.M.
        WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
        Lancet. 2013; 381: 1107-1115
        • MoriceMC Talwar S.
        • Gaemperli O.
        • Richardt G.
        • Eberli F.
        • Meredith I.
        • Zaman A.
        • Fajadet J.
        • Copt S.
        • Greene S.
        • Urban P.
        Drug-coated versus bare-metal stents for elderly patients: a predefined sub-study of the LEADERS FREE trial.
        Int. J. Cardiol. 2017; 243: 110-115
        • Lee S.Y.
        • Hong M.K.
        • Palmerini T.
        • Kim H.S.
        • Valgimigli M.
        • Feres F.
        • Colombo A.
        • Gilard M.
        • Shin D.H.
        • Kim J.S.
        • Kim B.K.
        • Ko Y.G.
        • Choi D.
        • Jang Y.
        • Stone G.W.
        Short-term versus long-term dual antiplatelet therapy after drug-eluting stent implantation in elderly patients: a meta-analysis of individual participant data from 6 randomized trials.
        JACC Cardiovasc. Interv. 2018; 11: 435-443
        • Pancholy S.B.
        • Shantha G.P.
        • Patel T.
        • Cheskin L.J.
        Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis.
        JAMA Intern Med. 2014; 174: 1822-1830
        • Roffi M.
        • Patrono C.
        • Collet J.P.
        • et al.
        2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC).
        Eur. Heart J. 2016; 37: 267-315
        • Morici N.
        • Savonitto S.
        • Ferri L.A.
        • Grosseto D.
        • Bossi I.
        • Sganzerla P.
        • Tortorella G.
        • Cacucci M.
        • Ferrario M.
        • Crimi G.
        • Murena E.
        • Tondi S.
        • Toso A.
        • Gandolfo N.
        • Ravera A.
        • Corrada E.
        • Mariani M.
        • Di Ascenzo L.
        • Petronio A.S.
        • Cavallini C.
        • Vitrella G.
        • Antonicelli R.
        • Piscione F.
        • Rogacka R.
        • Antolini L.
        • Alicandro G.
        • La Vecchia C.
        • Piatti L.
        • De Servi S.
        Elderly ACS-2 investigators. Outcomes of elderly patients with ST-elevation or non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention.
        Am. J. Med. 2019 Feb; 132: 209-216
        • Alabas O.A.
        • Gale C.P.
        • Hall M.
        • Rutherford M.J.
        • Szummer K.
        • Lawesson S.S.
        • Alfredsson J.
        • Lindahl B.
        • Jernberg T.
        Sex differences in treatments, relative survival, and excess mortality following acute myocardial infarction: national cohort study using the SWEDEHEART registry.
        J Am Heart Assoc. 2017; 61: 2
        • Josiah A.
        • Farshid A.
        Gender is Not a Predictor of Mortality or Major Adverse Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. Heart Lung Circ.
        2018 Apr 4 (pii: S1443-9506(18)30136-)
        • Bonaca M.P.
        • Bhatt D.L.
        • Cohen M.
        PEGASUS-TIMI 54 Steering Committee and Investigators Long-term use of ticagrelor in patients with prior myocardial infarction.
        N. Engl. J. Med. 2015; 372: 1791-1800
        • Mauri L.
        • Kereiakes D.J.
        • Yeh R.W.
        • et al.
        Twelve or 30 months of dual antiplatelet therapy after drug-elutingstents.
        N. Engl. J. Med. 2014; 371: 2155-2166
        • Didier R.
        • Morice M.C.
        • Barragan P.
        • et al.
        6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for DES after discontinuation of clopidogrel).
        JACC Cardiovasc. Interv. 2017; 10: 1202-1210